NASDAQ:CINC

CinCor Pharma - CINC Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $29.02
▼
$29.35
50-Day Range: $28.73
▼
$29.56
52-Week Range: $10.53
▼
$43.15

Volume: 6.35 million shs
Average Volume: 818,447 shs
Market Capitalization: $1.27 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.67

Institutional Ownership

CinCor Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 60.6% Upside
$46.67 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.14) to ($2.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

856th out of 999 stocks

Pharmaceutical Preparations Industry

418th out of 489 stocks

3.3

Analyst's Opinion

Consensus Rating
CinCor Pharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $46.67, CinCor Pharma has a forecasted upside of 60.6% from its current price of $29.06.
Amount of Analyst Coverage
CinCor Pharma has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for CINC.

0.0

Dividend Strength

Dividend Yield
CinCor Pharma does not currently pay a dividend.
Dividend Growth
CinCor Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CINC.

1.3

News and Social Media Coverage

News Sentiment
CinCor Pharma has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CinCor Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.60% of the stock of CinCor Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
99.15% of the stock of CinCor Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CinCor Pharma are expected to decrease in the coming year, from ($2.14) to ($2.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CinCor Pharma is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CinCor Pharma is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About CinCor Pharma (NASDAQ:CINC) Stock

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.

Receive CINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CinCor Pharma and its competitors with MarketBeat's FREE daily newsletter.

CINC Stock News Headlines

March 23, 2023 | americanbankingnews.com

CinCor Pharma, Inc. (NASDAQ:CINC) Receives $49.00 Average Price Target from Brokerages

March 16, 2023 | reuters.com

NASDAQ Biotechnology Index

March 30, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

March 13, 2023 | finance.yahoo.com

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

February 21, 2023 | finance.yahoo.com

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

February 9, 2023 | msn.com

As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023

January 24, 2023 | marketwatch.com

ADRs End Higher; AstraZeneca, Barclays Trade Actively

January 23, 2023 | msn.com

Britain's AstraZeneca launches tender offer for CinCor Pharma

March 30, 2023 | WealthPop (Ad)

Adam Mesh: “This Strategy Saved My Trading Career”

Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done.

January 23, 2023 | finance.yahoo.com

AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

January 12, 2023 | msn.com

Will 2023 be the year that pharma M&A makes a comeback?

January 12, 2023 | seekingalpha.com

AstraZeneca Is Acquiring CinCor Pharma: Market Values Interesting CVR At $3.21

January 11, 2023 | bizjournals.com

AstraZeneca reaches deal to buy CinCor Pharma for up to $1.8 billion

January 10, 2023 | finance.yahoo.com

AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout

January 10, 2023 | marketwatch.com

EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of CinCor Pharma, Inc - CINC

January 10, 2023 | finance.yahoo.com

AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout

January 9, 2023 | msn.com

AstraZeneca buying hypertension-focused CinCor for up to $1.8 billion

January 9, 2023 | finance.yahoo.com

AstraZeneca to Buy CinCor Pharma for Up to $1.8 Billion

January 9, 2023 | finance.yahoo.com

AstraZeneca reaches deal to buy CinCor Pharma for up to $1.8B

January 9, 2023 | finance.yahoo.com

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal

January 9, 2023 | finance.yahoo.com

Biotechs CinCor, Albireo Jump on Takeovers by Larger Drugmakers

January 9, 2023 | msn.com

AstraZeneca agrees to buy U.S.-based CinCor in deal valued at $1.3 billion

January 9, 2023 | wsj.com

AstraZeneca to Buy CinCor Pharma for Around $1.3 billion

January 9, 2023 | reuters.com

AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal

January 9, 2023 | barrons.com

These Stocks Are Moving the Most Monday: CinCor Pharma, Macy’s, Alibaba, and More

January 9, 2023 | markets.businessinsider.com

AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline

January 9, 2023 | finance.yahoo.com

CinCor Pharma Stock Surges on AstraZeneca Deal to Buy It

See More Headlines

Receive CINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CinCor Pharma and its competitors with MarketBeat's FREE daily newsletter.

CINC Company Calendar

Today: 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CINC
CUSIP: N/A
CIK: 1868734
Web: www.cincor.com
Phone: 844-531-1834
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $46.67
High Stock Price Forecast: $67.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +60.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($17.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -33.03%
Return on Assets: -27.21%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 51.96
Quick Ratio: 51.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.74) per share
Price / Book: -16.70

Miscellaneous

Outstanding Shares: 43,760,000
Free Float: 36,937,000
Market Cap: $1.27 billion
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Marc M. P. de Garidel (Age 64)
CEO & Director
Comp: $776.86k

Dr. Mason W. Freeman M.D. (Age 71)
Chief Medical Officer
Comp: $285.56k

Ms. Catherine Pearce DHSc (Age 46)
M.B.A., MBA, Co-Founder & COO

Mr. Michael W. Kalb CPA (Age 51)
Exec. VP, CFO & Principal Accounting Officer

Ms. Ida Hatoum
Sr. VP and Head of People, Talent & Culture

Hema Keshava
Corp. Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CINC Stock - Frequently Asked Questions

Should I buy or sell CinCor Pharma stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CinCor Pharma in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CINC shares.
View CINC analyst ratings or view top-rated stocks.
What is CinCor Pharma's stock price forecast for 2023?: 6 equities research analysts have issued 12 month target prices for CinCor Pharma's shares. Their CINC share price forecasts range from $30.00 to $67.00. On average, they predict the company's share price to reach $46.67 in the next twelve months. This suggests a possible upside of 60.6% from the stock's current price.
View analysts price targets for CINC or view top-rated stocks among Wall Street analysts.
When did CinCor Pharma IPO?: (CINC) raised $176 million in an IPO on the week of November 7th 2022. The company issued 11,000,000 shares at a price of $15.00-$17.00 per share.
What is CinCor Pharma's stock symbol?: CinCor Pharma trades on the NASDAQ under the ticker symbol "CINC."

Who are CinCor Pharma's major shareholders?: CinCor Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.25%), Sphera Funds Management LTD. (1.21%), Vivo Capital LLC (0.96%), Geode Capital Management LLC (0.96%), Silverarc Capital Management LLC (0.90%) and venBio Partners LLC (0.88%). Insiders that own company stock include 5Am Partners Vi, Llc, James Healy and Sofinnova Venture Partners X,.
View institutional ownership trends.
What is CinCor Pharma's stock price today?: One share of CINC stock can currently be purchased for approximately $29.06.
How much money does CinCor Pharma make?: CinCor Pharma (NASDAQ:CINC) has a market capitalization of $1.27 billion. The company earns $-50,370,000.00 in net income (profit) each year or ($17.28) on an earnings per share basis.
How can I contact CinCor Pharma?: The official website for the company is www.cincor.com. The company can be reached via phone at 844-531-1834 or via email at 0.

This page (NASDAQ:CINC) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CinCor Pharma - CINC Stock Forecast, Price & News

CinCor Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Company Ownership

Earnings and Valuation

About CinCor Pharma (NASDAQ:CINC) Stock

CINC Stock News Headlines

CINC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CINC Stock - Frequently Asked Questions

Overall MarketRank^™